Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Molecular Partners Ag (MOLN) EBIT: 2020-2025

Historic EBIT for Molecular Partners Ag (MOLN) over the last 5 years, with Sep 2025 value amounting to -$14,992.

  • Molecular Partners Ag's EBIT rose 31.41% to -$14,992 in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.5 million, marking a year-over-year decrease of 12.07%. This contributed to the annual value of -$69.6 million for FY2024, which is 2.27% down from last year.
  • Latest data reveals that Molecular Partners Ag reported EBIT of -$14,992 as of Q3 2025, which was up 99.95% from -$28.9 million recorded in Q2 2025.
  • In the past 5 years, Molecular Partners Ag's EBIT ranged from a high of $122.8 million in Q4 2022 and a low of -$64.0 million during Q4 2023.
  • Over the past 3 years, Molecular Partners Ag's median EBIT value was -$21,857 (recorded in 2024), while the average stood at -$17.3 million.
  • Per our database at Business Quant, Molecular Partners Ag's EBIT soared by 1,016.85% in 2022 and then plummeted by 386,240.97% in 2023.
  • Over the past 5 years, Molecular Partners Ag's EBIT (Quarterly) stood at -$13,549 in 2021, then dropped by 2.71% to $122.8 million in 2022, then plummeted by 152.12% to -$64.0 million in 2023, then grew by 3.78% to -$61.6 million in 2024, then surged by 31.41% to -$14,992 in 2025.
  • Its EBIT was -$14,992 in Q3 2025, compared to -$28.9 million in Q2 2025 and -$19,914 in Q1 2025.